Total Valuation
Arecor Therapeutics PLC has a market cap or net worth of €40.20M. The enterprise value is €20.50M.
Market Cap€40.20M
Enterprise Value€20.50M
Share Statistics
Arecor Therapeutics PLC has 45,300,716 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,300,716
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arecor Therapeutics PLC’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is -66.42%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)-66.42%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee51.94K
Profits Per Employee20.12K
Employee Count33
Asset Turnover0.21
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arecor Therapeutics PLC is 150.0. Arecor Therapeutics PLC’s PEG ratio is -0.43.
PE Ratio150.0
PS Ratio17.73
PB Ratio4.71
Price to FCF-12.72
Price to Operating Cash Flow-6.36
PEG Ratio-0.43
Income Statement
In the last 12 months, Arecor Therapeutics PLC had revenue of 1.71M and earned 664.00K in profits. Earnings per share was 0.02.
Revenue1.71M
Gross Profit1.05M
Operating Income-4.67M
Pretax Income994.00K
Net Income664.00K
EBITDA-4.45M
Earnings Per Share (EPS)0.02
Cash Flow
In the last 12 months, operating cash flow was -4.45M and capital expenditures -26.00K, giving a free cash flow of -4.48M billion.
Operating Cash Flow-4.45M
Free Cash Flow-4.48M
Free Cash Flow per Share-0.10
Dividends & Yields
Arecor Therapeutics PLC pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.12
52-Week Price Change27.35%
50-Day Moving Average0.73
200-Day Moving Average0.72
Relative Strength Index (RSI)40.99
Average Volume (3m)0.00
Important Dates
Arecor Therapeutics PLC upcoming earnings date is Apr 27, 2027, Before Open (Confirmed).
Last Earnings DateSep 30, 2026
Next Earnings DateApr 27, 2027
Ex-Dividend Date―
Financial Position
Arecor Therapeutics PLC as a current ratio of 4.35, with Debt / Equity ratio of 1.55%
Current Ratio4.35
Quick Ratio4.35
Debt to Market Cap0.00
Net Debt to EBITDA0.65
Interest Coverage Ratio-424.18
Taxes
In the past 12 months, Arecor Therapeutics PLC has paid 62.00K in taxes.
Income Tax62.00K
Effective Tax Rate0.06
Enterprise Valuation
Arecor Therapeutics PLC EV to EBITDA ratio is -6.18, with an EV/FCF ratio of -11.51.
EV to Sales16.04
EV to EBITDA-6.18
EV to Free Cash Flow-11.51
EV to Operating Cash Flow-12.00
Balance Sheet
Arecor Therapeutics PLC has €3.15M in cash and marketable securities with €57.00K in debt, giving a net cash position of €3.10M billion.
Cash & Marketable Securities€3.15M
Total Debt€57.00K
Net Cash€3.10M
Net Cash Per Share€0.07
Tangible Book Value Per Share€0.17
Margins
Gross margin is -800.00%, with operating margin of -272.23%, and net profit margin of 38.74%.
Gross Margin-800.00%
Operating Margin-272.23%
Pretax Margin57.99%
Net Profit Margin38.74%
EBITDA Margin-259.68%
EBIT Margin-272.23%
Analyst Forecast
The average price target for Arecor Therapeutics PLC is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―